Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 7c
May 16, 2022 7:31 AM EDTSyros Pharmaceuticals (NASDAQ: SYRS) reported Q1 EPS of ($0.40), $0.07 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $4.92 million.
For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.
... More